After announcing a licensing deal for CR9114, a monoclonal antibody for influenza A and B from Janssen (NYSE:JNJ), Leyden Labs has won $140 million in Series B funding. Amsterdam-based Leyden Labs plans on developing an intranasal spray based on CR9114. Leading the round were Casdin Capital and GV (formerly Google Ventures). Leyden plans on using…
Healthcare venture funding boomed in 2021; expect a slowdown in 2022
An all-time-high $86 billion of venture capital investments in the U.S. and Europe last year bested 2020’s record haul by more than 30 percent and grew more than 150 percent from 2019, according to a new analysis by Silicon Valley Bank. After record-setting quarters in the first half, however, VC investment slowed due to poor…